使用蛋白酶抑制剂向ITGB4/SOX2驱动的肺癌干细胞
Linlin Guo1,2, Atish Mohanty1, Sharad Singhal1
1Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA 91010, USA.
iScience
|August 9, 2023
概括
这项研究表明,向整合素β4 (ITGB4) 和SOX2可以克服肺状细胞癌 (LUSC) 中的抗性. 卡菲尔佐米布 (CFZ) 在使癌症干细胞对化疗敏感方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺状细胞癌 (LUSC) 呈现抗性,部分由癌症干细胞 (CSC) 介导.
- 集成蛋白β4 (ITGB4) 和SOX2在LUSC中表达很高,但它们在抗性中的特定作用需要阐明.
研究的目的:
- 调查ITGB4和SOX2在LUSC中的抗性中的作用.
- 通过向ITGB4和SOX2.2,评估Carfilzomib (CFZ) 在克服抗性的疗效.
主要方法:
- 在LUSC亚型中分析ITGB4和SOX2表达和患者存活率.
- 用西斯普拉丁,ITGB4/SOX2 Knockdown 和CFZ隔离和治疗LUSC CSCs.
- 通过CFZ对SOX2调节的表观遗传机制的评估.
主要成果:
- 在LUSC中,高SOX2和ITGB4表达,ITGB4对亚型的生存有不同的影响.
- 对ITGB4或SOX2敏感的抗西斯普拉丁的LUSC CSCs的淘汰.
- 卡菲尔佐米布 (CFZ) 与西斯普拉丁协同作用,抑制ITGB4和SOX2,并抑制CSC生长.
- 通过降低基因素乙化,CFZ通过表观遗传抑制了SOX2表达,并抑制了SOX2依赖的小细胞肺癌生长.
结论:
- ITGB4和SOX2是LUSC CSC中金抗性的关键驱动因素.
- 通过抑制ITGB4/SOX2和表观遗传抑制SOX2.2,CFZ在克服白金耐药性方面发挥了双重作用.
- CFZ代表了对抗性LUSC和SOX2驱动癌症的潜在治疗策略.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
8.4K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
